Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 24, 2011

View Archived Issues

Clinical findings presented for sirukumab in lupus and rheumatoid arthritis

New mechanism explored for treating Alzheimer's disease

New LXR agonist displays promising antiatherosclerotic effects in vivo

Korean investigators discover new biomarker of disease activity in rheumatoid arthritis

Results reported from phase I trial of enavatuzumab in advanced solid tumors

Updated results presented from ongoing first-in-patient trial of PF-04691502

Amgen tests antibody-drug conjugate targeting EGFRvIII

New compounds for bone disorders prepared by Daiichi Sankyo

Astellas Pharma prepares novel NPT-IIb inhibitors

FDA approves Medtronic's iPro2 professional CGM system

Novel tyrosine-protein kinase SYK inhibitors designed by GSK

Transition Therapeutics set to close USD 5 million private placement

UCB decides on option agreement to license SYN-118

Japanese researchers synthesize new PDE4B inhibitors

Takeda Pharmaceuticals reports novel acetyl-CoA carboxylase inhibitors

Advaxis completes pre-IND meeting for ADXS-HER2

Neuralstem injects first patient with stem cells in cervical region of spine

Takeda files NDA for fixed-dose tablet of alogliptin/metformin

FDA approves Transcept's insomnia drug Intermezzo

Mesoblast and FDA agree on adult stem cell trial in type 2 diabetes

Summit's SMT-C1100 granted orphan drug status in Duchenne's muscular dystrophy

Phase II trial of RP-G28 in lactose intolerance completed

Aeterna Zentaris licenses anticancer agent to Hikma

Cipher submits amendment to NDA for novel acne treatment

NICE decides not to recommend Lucentis for treatment of macular edema

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...